82
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Heart failure hospitalization reduction and cost savings achieved by improved delivery of effective biventricular pacing: economic implications of the OLE study under the US setting

, , , , , & show all
Pages 385-393 | Published online: 06 Jun 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Unchalee Permsuwan, Arintaya Phrommintikul & Voratima Silavanich. (2020) Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Heart Failure in Thailand. ClinicoEconomics and Outcomes Research 12, pages 579-588.
Read now

Articles from other publishers (5)

Takashi Noda, Xiaoxiao Lu, Yoko Ishiguro, Joshua Ikuemonisan, Reece Holbrook, Stelios Tsintzos & Kengo Kusano. (2022) Cost-effective analysis of automated programming optimization in cardiac resynchronization therapy: Holistic Markov modelling. Journal of Cardiology 79:6, pages 734-739.
Crossref
Jan Ciszewski & Maciej Sterliński. (2021) Management of Atrial Fibrillation in Recipients of Cardiac Resynchronization Therapy. European Journal of Arrhythmia & Electrophysiology 7:1, pages 19.
Crossref
Eugene S. Chung, John Rickard, Xiaoxiao Lu, Maral DerSarkissian, Miriam L. Zichlin, Hoi Ching Cheung, Natalia Swartz, Alexandra Greatsinger & Mei S. Duh. (2020) Real-World Economic Burden Among Patients With And Without Heart Failure Worsening After Cardiac Resynchronization Therapy. Advances in Therapy 38:1, pages 441-467.
Crossref
Carlos Escobar, Luis Varela, Beatriz Palacios, Margarita Capel, Antoni Sicras, Aram Sicras, Antonio Hormigo, Roberto Alcázar, Nicolás Manito & Manuel Botana. (2020) Costs and healthcare utilisation of patients with heart failure in Spain. BMC Health Services Research 20:1.
Crossref
Michael Urbich, Gary Globe, Krystallia Pantiri, Marieke Heisen, Craig Bennison, Heidi S. Wirtz & Gian Luca Di Tanna. (2020) A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020). PharmacoEconomics 38:11, pages 1219-1236.
Crossref